178 related articles for article (PubMed ID: 33627993)
1. Comparison of Protocols to Reduce Diabetic Ketoacidosis in Patients With Type 1 Diabetes Prescribed a Sodium-Glucose Cotransporter 2 Inhibitor.
Teng R; Kurian M; Close KL; Buse JB; Peters AL; Alexander CM
Diabetes Spectr; 2021 Jan; 34(1):42-51. PubMed ID: 33627993
[No Abstract] [Full Text] [Related]
2. Sodium-glucose cotransporter-2 inhibitor-associated euglycemic diabetic ketoacidosis in COVID-19-infected patients: A systematic review of case reports.
Khedr A; Hennawi HA; Khan MK; Eissa A; Mir M; Rauf I; Nitesh J; Surani S; Khan SA
World J Clin Cases; 2023 Aug; 11(24):5700-5709. PubMed ID: 37727728
[TBL] [Abstract][Full Text] [Related]
3. On-label use of sodium-glucose cotransporter 2 inhibitors might increase the risk of diabetic ketoacidosis in patients with type 1 diabetes.
Horii T; Oikawa Y; Atsuda K; Shimada A
J Diabetes Investig; 2021 Sep; 12(9):1586-1593. PubMed ID: 33448127
[TBL] [Abstract][Full Text] [Related]
4. Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes.
Peters AL; Henry RR; Thakkar P; Tong C; Alba M
Diabetes Care; 2016 Apr; 39(4):532-8. PubMed ID: 26989182
[TBL] [Abstract][Full Text] [Related]
5. Sodium-Glucose Cotransporter-2 Inhibitors and Risk of Diabetic Ketoacidosis Among Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Colacci M; Fralick J; Odutayo A; Fralick M
Can J Diabetes; 2022 Feb; 46(1):10-15.e2. PubMed ID: 34116926
[TBL] [Abstract][Full Text] [Related]
6. SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.
Goldenberg RM; Berard LD; Cheng AYY; Gilbert JD; Verma S; Woo VC; Yale JF
Clin Ther; 2016 Dec; 38(12):2654-2664.e1. PubMed ID: 28003053
[TBL] [Abstract][Full Text] [Related]
7. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
Burke KR; Schumacher CA; Harpe SE
Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
[TBL] [Abstract][Full Text] [Related]
8. Re-examining the widespread policy of stopping sodium-glucose cotransporter-2 inhibitors during acute illness: A perspective based on the updated evidence.
Khunti K; Aroda VR; Bhatt DL; Bozkurt B; Buse JB; Heerspink HL; Inzucchi SE; Lam CSP; Marx N; McMurray JJV; Solomon SD; Kosiborod MN
Diabetes Obes Metab; 2022 Nov; 24(11):2071-2080. PubMed ID: 35801339
[TBL] [Abstract][Full Text] [Related]
9. A Case of Prolonged Recovery for Post-percutaneous Coronary Intervention (PCI) Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor-Induced Euglycemic Diabetic Ketoacidosis in a 28-Year-Old.
Petersen C; Gyabaah F; Sotelo J; Yohanna S; Deoker A
Cureus; 2023 Sep; 15(9):e45180. PubMed ID: 37842482
[TBL] [Abstract][Full Text] [Related]
10. A Literature Review of the Therapeutic Perspectives of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor-Induced Euglycemic Diabetic Ketoacidosis.
Patel K; Nair A
Cureus; 2022 Sep; 14(9):e29652. PubMed ID: 36320965
[TBL] [Abstract][Full Text] [Related]
11. Sodium-glucose cotransporter-2 (SGLT2) inhibitor-induced euglycemic diabetic ketoacidosis complicating the perioperative management of a patient with type 2 diabetes mellitus (T2DM) and Fournier's gangrene: A case report.
Lindsay PJ; Gibson LE; Bittner EA; Berg S; Chang MG
Int J Surg Case Rep; 2020; 77():463-466. PubMed ID: 33395826
[TBL] [Abstract][Full Text] [Related]
12. Euglycemic ketosis in patients with type 2 diabetes on SGLT2-inhibitor therapy-an emerging problem and solutions offered by diabetes technology.
Pfützner A; Klonoff D; Heinemann L; Ejskjaer N; Pickup J
Endocrine; 2017 Apr; 56(1):212-216. PubMed ID: 28303514
[TBL] [Abstract][Full Text] [Related]
13. Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis.
Hampp C; Swain RS; Horgan C; Dee E; Qiang Y; Dutcher SK; Petrone A; Chen Tilney R; Maro JC; Panozzo CA
Diabetes Care; 2020 Jan; 43(1):90-97. PubMed ID: 31601640
[TBL] [Abstract][Full Text] [Related]
14. SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis.
Liu H; Sridhar VS; Perkins BA; Rosenstock J; Cherney DZI
Curr Diab Rep; 2022 Jul; 22(7):317-332. PubMed ID: 35633439
[TBL] [Abstract][Full Text] [Related]
15. Overlapping risk factors for diabetic ketoacidosis in patients with type 1 diabetes on ipragliflozin: case analysis of spontaneous reports in Japan from a pharmacovigilance safety database.
Abiru N; Nakatsuji Y; Noguchi M; Tsuboi K
Expert Opin Drug Saf; 2023; 22(8):697-706. PubMed ID: 36946980
[TBL] [Abstract][Full Text] [Related]
16. Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature.
Diaz-Ramos A; Eilbert W; Marquez D
Int J Emerg Med; 2019 Sep; 12(1):27. PubMed ID: 31488052
[TBL] [Abstract][Full Text] [Related]
17. Commentary: SGLT inhibitors in type 1 diabetes: Place in therapy and a risk mitigation strategy for preventing diabetic ketoacidosis - the STOP DKA protocol.
Rendell MS
Diabetes Obes Metab; 2019 Oct; 21(10):2189-2191. PubMed ID: 31334593
[TBL] [Abstract][Full Text] [Related]
18. Beyond type 2 diabetes: sodium glucose co-transporter-inhibition in type 1 diabetes.
Biester T; Kordonouri O; Danne T
Diabetes Obes Metab; 2019 Apr; 21 Suppl 2():53-61. PubMed ID: 31081591
[TBL] [Abstract][Full Text] [Related]
19. "Normal but Catastrophic" Euglycemic Diabetic Ketoacidosis Precipitated by Sodium-Glucose Cotransporter-2 Inhibitor Use: A Case Report.
Sarno MJF; Hernandez DPF; Matulac MO
Cureus; 2023 Nov; 15(11):e49236. PubMed ID: 38143642
[TBL] [Abstract][Full Text] [Related]
20. Evolving Evidence of Diabetic Ketoacidosis in Patients Taking Sodium-Glucose Cotransporter 2 Inhibitors.
Fleming N; Hamblin PS; Story D; Ekinci EI
J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32302001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
